PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLCSeptember 28, 2018Immuno-oncologyLung Cancer
CGP guides cancer patient management, facilitates trial enrollmentSeptember 24, 2018Lung CancerPatient & Survivor Care
First combo trial of mTOR/BRAF inhibition shows potentialSeptember 23, 2018MelanomaLung CancerCNS/Brain CancerGastroenterologyHead & Neck/Thyroid CancersGastrointestinal Cancer
PD-1/PD-L1 treatment linked to hyperprogressive disease in lung cancer patientsSeptember 20, 2018Immuno-oncologyLung Cancer
Fatal toxicities from checkpoint inhibitors vary by agentSeptember 19, 2018Immuno-oncologyMelanomaLung Cancer
ESMO scale offers guidance on cancer targetsSeptember 6, 2018Lung CancerBreast CancerPatient & Survivor CareMelanomaGastroenterologyGastrointestinal Cancer
PD1 mRNA may predict response to anti-PD1 monotherapy across cancer typesSeptember 4, 2018Immuno-oncologyMelanomaLung CancerRenal Cell Carcinoma
Adding checkpoint inhibitors to radiotherapy requires particular caution in this one scenarioAugust 24, 2018Immuno-oncologyLung CancerCNS/Brain CancerMelanoma
